Literature DB >> 8483992

Albendazole is effective treatment for chronic strongyloidiasis.

L K Archibald1, N J Beeching, G V Gill, J W Bailey, D R Bell.   

Abstract

A total of 301 British ex-Far East prisoners of war, many of whom worked on the Thai-Burma Railway during World War II, consecutively attended The Liverpool School of Tropical Medicine for clinical review between January 1987 and August 1990. Fifty-two (17%) were found to have chronic strongyloidiasis. Diagnostic criteria included any of the following: characteristic larva currens rash, positive Strongyloides serology, and positive stool examination. Forty-seven were evaluable 6 months, after therapy with albendazole 400 mg twice daily for 3 days, which resulted in a 75% cure rate. Cure was defined as disappearance of the rash, if present, negative serology and negative stool examination. Patients who had more than one positive diagnostic feature were only considered cured if both or all had disappeared or become negative. All 12 of the patients in whom initial treatment failed were given a second course of albendazole: three further cures were obtained in eight evaluable patients. The overall cure rate was 81%. The only side-effects recorded were mild nausea and diarrhoea in one patient. We suggest that albendazole should be the treatment of choice for chronic strongyloidiasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8483992

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  10 in total

1.  Pulmonary Strongyloidiasis: The Varied Clinical Presentations.

Authors:  Babak Mokhlesi; Oksana Shulzhenko; Prasad S Garimella; Leslie Kuma; Catherine Monti
Journal:  Clin Pulm Med       Date:  2004-01

Review 2.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 3.  Strongyloides stercoralis in the Immunocompromised Population.

Authors:  Paul B Keiser; Thomas B Nutman
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

4.  Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial.

Authors:  P Kelly; F Lungu; E Keane; R Baggaley; F Kazembe; J Pobee; M Farthing
Journal:  BMJ       Date:  1996-05-11

5.  Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.

Authors:  Yupin Suputtamongkol; Nalinee Premasathian; Kid Bhumimuang; Duangdao Waywa; Surasak Nilganuwong; Ekkapun Karuphong; Thanomsak Anekthananon; Darawan Wanachiwanawin; Saowaluk Silpasakorn
Journal:  PLoS Negl Trop Dis       Date:  2011-05-10

Review 6.  Strongyloides stercoralis: systematic review of barriers to controlling strongyloidiasis for Australian indigenous communities.

Authors:  Adrian Miller; Michelle L Smith; Jenni A Judd; Rick Speare
Journal:  PLoS Negl Trop Dis       Date:  2014-09-25

7.  Disseminated Strongyloidiasis in an Immunodeficient Patient (Pemphigus Vulgaris) Due to Corticosteroid Therapy: A Case Report.

Authors:  Mohsen Najjari; Mohammad Ebrahimipour; Amir Kaheh; Mohammadreza Karimazar
Journal:  Iran J Parasitol       Date:  2016 Jul-Sep       Impact factor: 1.012

8.  Efficacy of Single Dose Ivermectin Against Strongyloides stercoralis Infection Among Primary School Children in Amhara National Regional State.

Authors:  Tadesse Hailu; Endalkachew Nibret; Arancha Amor; Abaineh Munshea; Melaku Anegagrie
Journal:  Infect Dis (Auckl)       Date:  2020-06-15

Review 9.  Neglected tropical diseases: survey and geometry of randomised evidence.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  BMJ       Date:  2012-10-22

Review 10.  Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.

Authors:  Cesar Henriquez-Camacho; Eduardo Gotuzzo; Juan Echevarria; A Clinton White; Angelica Terashima; Frine Samalvides; José A Pérez-Molina; Maria N Plana
Journal:  Cochrane Database Syst Rev       Date:  2016-01-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.